Accuray Gelecekteki Büyüme
Future kriter kontrolleri 0/6
Şu anda Accuray için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.
Anahtar bilgiler
n/a
Kazanç büyüme oranı
n/a
EPS büyüme oranı
| Medical Equipment kazanç büyümesi | 17.0% |
| Gelir büyüme oranı | n/a |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 07 Jul 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Anlatı Güncellemesi • Jun 26
ARAY: Reset P/E Expectations And Guidance Withdrawal Will Shape Future Risk Balance
The analyst price target on Accuray has been cut by about $3.53 to reflect a lower implied fair value, a higher discount rate, and sharply reduced future P/E expectations, following recent downgrades where analysts cited softer growth and margin assumptions. Analyst Commentary Recent research on Accuray has focused on how realistic growth and margin assumptions should feed into valuation, especially after the latest downgrades and the reset in future P/E expectations.Analiz Makalesi • May 13
Need To Know: Analysts Just Made A Substantial Cut To Their Accuray Incorporated (NASDAQ:ARAY) Estimates
Today is shaping up negative for Accuray Incorporated ( NASDAQ:ARAY ) shareholders, with the analysts delivering a...
Yeni Anlatı • Feb 21
Future Service Contracts And Operational Transformation Will Reshape Long Term Cancer Care Access
Catalysts About Accuray Accuray develops and sells radiation therapy systems and related services used by hospitals and cancer centers worldwide. What are the underlying business or industry changes driving this perspective?Analiz Makalesi • Feb 06
The Market Doesn't Like What It Sees From Accuray Incorporated's (NASDAQ:ARAY) Revenues Yet As Shares Tumble 33%
Unfortunately for some shareholders, the Accuray Incorporated ( NASDAQ:ARAY ) share price has dived 33% in the last...Seeking Alpha • Feb 06
Groundhog Day Once Again, As Accuray Misses And Lowers
Summary Accuray continues to disappoint with weaker revenue, weaker orders and market share, lowered guidance, and little evidence of a turnaround. ARAY's restructuring aims for $25M in annual profitability improvements, but lacks novel strategies and may risk further sales declines. Competitive pressure from Siemens Healthineers and Elekta underscores ARAY's inability to gain traction, especially in critical markets like China. Despite undervaluation, persistent cash burn and lack of turnaround visibility make the risk/reward unattractive; I plan to exit my small position. Read the full article on Seeking Alpha
Yeni Anlatı • Feb 06
Service Transformation And China Delays Will Reshape Margins Yet Eventually Support A Healthier Business
Catalysts About Accuray Accuray develops and sells radiation therapy systems and related services for cancer treatment facilities worldwide. What are the underlying business or industry changes driving this perspective?Analiz Makalesi • Dec 20
Accuray (NASDAQ:ARAY) May Have Issues Allocating Its Capital
If you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...Analiz Makalesi • Dec 02
Little Excitement Around Accuray Incorporated's (NASDAQ:ARAY) Revenues As Shares Take 28% Pounding
The Accuray Incorporated ( NASDAQ:ARAY ) share price has fared very poorly over the last month, falling by a...Analiz Makalesi • Nov 27
Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Oct 10
Benign Growth For Accuray Incorporated (NASDAQ:ARAY) Underpins Its Share Price
Accuray Incorporated's ( NASDAQ:ARAY ) price-to-sales (or "P/S") ratio of 0.5x might make it look like a strong buy...Analiz Makalesi • Aug 13
Returns At Accuray (NASDAQ:ARAY) Are On The Way Up
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analiz Makalesi • Jun 28
Accuray Incorporated's (NASDAQ:ARAY) Share Price Is Matching Sentiment Around Its Revenues
With a price-to-sales (or "P/S") ratio of 0.3x Accuray Incorporated ( NASDAQ:ARAY ) may be sending very bullish signals...Analiz Makalesi • Apr 04
Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Analiz Makalesi • Mar 11
Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 26% Price Drop
Accuray Incorporated ( NASDAQ:ARAY ) shares have had a horrible month, losing 26% after a relatively good period...Analiz Makalesi • Jan 18
Accuray Incorporated (NASDAQ:ARAY) Shares Fly 25% But Investors Aren't Buying For Growth
Accuray Incorporated ( NASDAQ:ARAY ) shares have had a really impressive month, gaining 25% after a shaky period...Seeking Alpha • Jan 07
Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If'
Summary Impressive revenue growth remains elusive for Accuray despite the potential in China, and there are ongoing challenges with profitability, competition, and market scale. The last quarter's results showed mixed performance, with better than expected revenue and a small guidance boost, but overall product sales were down and the backlog shrank modestly. Sustainability remains a key issue; China is growing nicely, but revenue in Japan weakened and the company has seen its installed base in the U.S. shrink, pressuring service revenue. Accuray appears undervalued but faces significant risks; the potential for better results exists, particularly if China efforts succeed and U.S. sales stabilize, but improvement in execution has long been elusive. Read the full article on Seeking AlphaAnaliz Makalesi • Dec 19
Health Check: How Prudently Does Accuray (NASDAQ:ARAY) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Dec 05
Accuray Incorporated: Cheap, But With Caveats
Summary Today, we take a deeper look at Accuray Incorporated, a medical device company that manufactures radiosurgery and radiation therapy systems. Despite mid-single-digit sales growth, Accuray trades at under 50% of current revenues and is nearing profitability, but the company has a significant debt load. A couple of analyst firms believe the stock should be trading at much higher levels. An analysis around Accuray Incorporated follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Aug 18
Accuray Remains A Perpetual 'Next Year Is Our Year' Story
Summary Accuray posts a strong end to the fiscal year with 16% revenue growth in FQ4, beating expectations and restoring some confidence for the upcoming year. Management's claim that weaker U.S. sales are a consequence of a weaker capex environment don't fully align with the reported U.S. sales results of other med-tech capital equipment companies. Global opportunities remain promising, especially in China's value-priced linac market, and opportunities in Japan, India, other emerging markets are meaningful. Execution remains critical as the company faces tough competition and needs to capitalize on growth opportunities in China and replacement/renewal opportunities in the U.S. market. Accuray shares offer potential upside, at the cost of elevated risk, if the company can overcome sales execution challenges and capitalize on emerging market opportunities. Read the full article on Seeking AlphaAnaliz Makalesi • Aug 13
Accuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching Revenues
Accuray Incorporated ( NASDAQ:ARAY ) shareholders won't be pleased to see that the share price has had a very rough...Analiz Makalesi • May 21
Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop
To the annoyance of some shareholders, Accuray Incorporated ( NASDAQ:ARAY ) shares are down a considerable 25% in the...Analiz Makalesi • May 04
Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results
It's shaping up to be a tough period for Accuray Incorporated ( NASDAQ:ARAY ), which a week ago released some...Analiz Makalesi • May 03
Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Accuray fair value estimate is US$2.06 Accuray's US$1.54 share...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 6/30/2027 | 413 | -38 | N/A | N/A | 1 |
| 6/30/2026 | 402 | -49 | -19 | -7 | N/A |
| 3/31/2026 | 429 | -46 | -33 | -19 | N/A |
| 12/31/2025 | 437 | -36 | -11 | 5 | N/A |
| 9/30/2025 | 451 | -19 | 11 | 22 | N/A |
| 6/30/2025 | 459 | -2 | -6 | 3 | N/A |
| 3/31/2025 | 465 | 1 | 17 | 22 | N/A |
| 12/31/2024 | 453 | -4 | -8 | -4 | N/A |
| 9/30/2024 | 444 | -17 | -14 | -11 | N/A |
| 6/30/2024 | 447 | -16 | -16 | -12 | N/A |
| 3/31/2024 | 431 | -21 | -24 | -13 | N/A |
| 12/31/2023 | 447 | -15 | 8 | 20 | N/A |
| 9/30/2023 | 455 | -7 | -6 | 7 | N/A |
| 6/30/2023 | 448 | -9 | 3 | 16 | N/A |
| 3/31/2023 | 439 | -10 | -4 | 2 | N/A |
| 12/31/2022 | 417 | -12 | -50 | -44 | N/A |
| 9/30/2022 | 419 | -10 | 2 | 6 | N/A |
| 6/30/2022 | 430 | -5 | -7 | -2 | N/A |
| 3/31/2022 | 431 | -13 | 4 | 8 | N/A |
| 12/31/2021 | 437 | -12 | 43 | 46 | N/A |
| 9/30/2021 | 418 | -8 | 30 | 33 | N/A |
| 6/30/2021 | 396 | -6 | 36 | 39 | N/A |
| 3/31/2021 | 380 | 5 | 49 | 51 | N/A |
| 12/31/2020 | 377 | 8 | 21 | 23 | N/A |
| 9/30/2020 | 379 | 14 | 17 | 20 | N/A |
| 6/30/2020 | 383 | 4 | -5 | -1 | N/A |
| 3/31/2020 | 405 | 3 | N/A | -11 | N/A |
| 12/31/2019 | 409 | -1 | N/A | -6 | N/A |
| 9/30/2019 | 413 | -17 | N/A | -36 | N/A |
| 6/30/2019 | 419 | -16 | N/A | -30 | N/A |
| 3/31/2019 | 415 | -16 | N/A | -11 | N/A |
| 12/31/2018 | 412 | -24 | N/A | 0 | N/A |
| 9/30/2018 | 410 | -24 | N/A | 14 | N/A |
| 6/30/2018 | 405 | -24 | N/A | 18 | N/A |
| 3/31/2018 | 403 | -28 | N/A | 14 | N/A |
| 12/31/2017 | 401 | -24 | N/A | -3 | N/A |
| 9/30/2017 | 388 | -29 | N/A | -7 | N/A |
| 6/30/2017 | 383 | -30 | N/A | 0 | N/A |
| 3/31/2017 | 366 | -32 | N/A | -4 | N/A |
| 12/31/2016 | 374 | -26 | N/A | 0 | N/A |
| 9/30/2016 | 396 | -22 | N/A | 12 | N/A |
| 6/30/2016 | 399 | -26 | N/A | 31 | N/A |
| 3/31/2016 | 406 | -24 | N/A | 7 | N/A |
| 12/31/2015 | 398 | -28 | N/A | 17 | N/A |
| 9/30/2015 | 387 | -32 | N/A | 10 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: ARAY 'un tahmini kazanç büyümesinin tasarruf oranının ( 3.7% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.
Kazançlar ve Piyasa: ARAY 'un kazançlarının US pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok
Yüksek Büyüme Kazançları: ARAY şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.
Gelir ve Pazar: ARAY şirketinin gelirinin US pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.
Yüksek Büyüme Geliri: ARAY şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: ARAY 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/13 04:54 |
| Gün Sonu Hisse Fiyatı | 2026/09/11 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2026/06/30 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Accuray Incorporated 16 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Neil Chatterji | B. Riley Securities, Inc. |
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |